Tags : FLAURA

AstraZeneca Reports Updated Positive Results of Tagrisso (osimertinib) in P-III

Tuba Khan August 9, 2019

Shots: The P-III FLAURA study involves assessing of Tagrisso (80mg, qd) vs EGFR-TKIs (erlotinib, 50mg, qd /gefitinib, 250mg, qd) in 556 patients with LA/metastatic EGFRm NSCLC across 29 countries In […]readmore

Tags : FLAURA

AstraZeneca Reports Updated Positive Results of Tagrisso (osimertinib) in P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : FLAURA

﻿AstraZeneca Reports Updated Positive Results of Tagrisso (osimertinib) in P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

AstraZeneca Reports Updated Positive Results of Tagrisso (osimertinib) in P-III